Poster | 6th Internet World Congress for Biomedical Sciences |
Trevor Sharp(1), Elena Castro(2)
(1)Department of Clinical Pharmacology. University of Oxford - Oxford. United Kingdom
(2) Clinical Pharmacology. University of Oxford - Oxford. United Kingdom
![]() |
![]() |
![]() |
![]() |
[Pharmacology]![]() |
[Psychiatry]![]() |
In conclusion, our results show that the putative SSRI augmenting agent, (±)-pindolol, has high affinity for both presynaptic and postsynaptic 5-HT1A receptors in postmortem human and rat brain. Our data do not support the idea that pindolol has marked selectivity for any of the 5-HT1A receptor populations studied in vitro. However, recent PET imaging studies in human volunteers indicate that over a narrow dose range, pindolol may preferentially occupy presynaptic 5-HT1A receptors in vivo (13). Whether this property of pindolol confers therapeutic advantages (ie. in major depression) over other 5-HT1A receptor antagonists currently available for clinical use (eg. tertatolol and penbutolol), awaits further investigation.
![]() |
![]() |
![]() |
![]() |
[Pharmacology]![]() |
[Psychiatry]![]() |